Jolly Healthcare launches India’s first pharma-grade ketogenic diet formulation

In August 2026, Jolly Healthcare launched KETOJOL 4:1, a ketogenic diet formulation with a 4:1 fat-to-protein + carbohydrate ratio, and is intended for use in clinical nutrition and pediatric neurology. The formulation is manufactured under a stringent pharmaceutical manufacturing license.

According to reports, drug-resistant epilepsy, also known as DRE, affects nearly one in three epilepsy patients, who continue to experience uncontrolled seizures despite treatment with multiple Anti-Epileptic Drugs (AEDs). Published clinical journals and papers further indicate that classical Ketogenic Dietary Therapy (KDT), in which around 90 per cent of total calories are derived from fat, can result in a ≥50 per cent reduction in seizure frequency in 50–60 per cent of children who suffer from refractory epilepsy.

The company’s formulation contains the prebiotic Inulin and an enriched micronutrient profile, and these components are intended to support gastrointestinal tolerance and nutritional requirements during ketogenic dietary therapy. Jolly Healthcare also stated that the product will initially be made available through tertiary care hospitals, pediatric neurology centers, and specialized dietetic clinics.

Impact on the Healthcare Market

Engineered as a comprehensive medical nutrition solution, KETOJOL 4:1 addresses the key clinical limitations of traditional ketogenic diets. The inclusion of prebiotics (Inulin) further improves gastrointestinal tolerance, while its enriched micronutrient profile helps mitigate long-term nutritional deficiencies commonly associated with strict ketogenic regimens.

The launch is further supported by the 'KETOJOL Keto Support Program', which helps provide precision digital weighing protocols (0.1g accuracy) and caregiver education to ensure exact dosage administration. Strictly classified as a KETOJOL 4:1 is intended for use under qualified medical supervision as an adjunct dietary therapy alongside prescribed clinical management. The company also stated that the product aims to offer pediatric neurologists and dietitians a standardized, practical nutritional solution for children needing ketogenic dietary treatment.

Impact on the Epilepsy Drug Market

The global epilepsy drug market size is estimated at USD 11.88 billion in 2025 and predicted to increase from USD 12.49 billion in 2026 to approximately USD 19.67 billion by 2035, expanding at a CAGR of 5.17% over the forecast period from 2026 to 2035.

According to Precedence Research, the market is involved in the production, distribution, and sale of medications specifically designed for the treatment of epilepsy and the management of epileptic seizures. It encompasses pharmaceutical companies that research, develop, manufacture, and market antiepileptic drugs (AEDs), as well as the various healthcare professionals, clinics, pharmacies, hospitals, and patients that participate in the purchase and use of these medications. The market is further being influenced by several factors such as the prevalence of epilepsy, the development of new and more effective medications, patent expirations, pricing, and access to treatment. It is a crucial component of the broader pharmaceutical industry, serving the needs of patients with epilepsy worldwide.

As the incidence of epilepsy continues to grow, driven by factors like an aging population and better diagnostic methods, there is an increasing need for effective epilepsy drug treatments. Continuous research efforts by pharmaceutical companies to develop more effective and safer antiepileptic drugs lead to the introduction of new and improved medications, expanding the market. The development of innovative drug formulations, such as extended-release tablets or new drug delivery methods, can enhance patient compliance and treatment outcomes, driving market growth.

Impact on the Drug Formulation Market

The global drug formulation market size is calculated at USD 1.96 trillion in 2025 and is predicted to increase from USD 2.08 trillion in 2026 to approximately USD 3.50 trillion by 2035, expanding at a CAGR of 5.97% from 2026 to 2035.

According to Precedence Research, the advent of cutting-edge technologies and more accessible and economical manufacturing techniques has resulted in a significant shift in the pharmaceutical sector. To reduce production waste and downtime on the factory floor, robotics and artificial intelligence are rapidly being deployed in the pharmaceutical business.

By providing several opportunities to treat a wide range of medical diseases, personalized medicine has also made it possible to create patient-centric models. Additionally, the prevalence of chronic diseases in the population is rising, and the amount of investment flowing into this industry is increasing, which is helping to fuel market expansion. The growing global population, which recently has aided the drug formulation industry's growth, is also impacting the consumption of medicines.

Expert Opinion

Addressing the launch, Avish Jolly, MD and CEO, Jolly Healthcare, stated,

“For decades, families managing Drug-Resistant Epilepsy have faced severe execution barriers-from complex home calculations and poor pediatric palatability to long-term nutritional deficits and gastrointestinal distress. By securing classification under a pharmaceutical manufacturing license, KETOJOL 4:1 bridges the gap between strict clinical efficacy and real-world compliance. Enhanced with prebiotics (Inulin) for superior GI tolerance and formulated for child acceptance, our goal is to empower pediatric neurologists and dietitians with a practical, high-precision solution that supports uninterrupted childhood.”